Open Collections

UBC Faculty Research and Publications

A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro Yang, Xiaolong; Liu, Lidong; Hao, Yawei; So, Eva; Emami, Sahar Sarmasti; Zhang, Derek; Gong, Yanping; Sheth, Prameet M.; Wang, Yutian

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is currently spreading and mutating with increasing speed worldwide. Therefore, there is an urgent need for a simple, sensitive, and high-throughput (HTP) assay to quantify virus–host interactions in order to quickly evaluate the infectious ability of mutant viruses and to develop or validate virus-inhibiting drugs. Here, we developed an ultrasensitive bioluminescent biosensor to evaluate virus–cell interactions by quantifying the interaction between the SARS-CoV-2 receptor binding domain (RBD) and its cellular receptor angiotensin-converting enzyme 2 (ACE2) both in living cells and in vitro. We have successfully used this novel biosensor to analyze SARS-CoV-2 RBD mutants and evaluated candidate small molecules (SMs), antibodies, and peptides that may block RBD:ACE2 interaction. This simple, rapid, and HTP biosensor tool will significantly expedite the detection of viral mutants and the anti-COVID-19 drug discovery process.

Item Metadata

Title
A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro
Creator
Yang, Xiaolong; Liu, Lidong; Hao, Yawei; So, Eva; Emami, Sahar Sarmasti; Zhang, Derek; Gong, Yanping; Sheth, Prameet M.; Wang, Yutian
Contributor
Djavad Mowafaghian Centre for Brain Health
Publisher
Multidisciplinary Digital Publishing Institute
Date Issued
2021-06-02
Description
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is currently spreading and mutating with increasing speed worldwide. Therefore, there is an urgent need for a simple, sensitive, and high-throughput (HTP) assay to quantify virus–host interactions in order to quickly evaluate the infectious ability of mutant viruses and to develop or validate virus-inhibiting drugs. Here, we developed an ultrasensitive bioluminescent biosensor to evaluate virus–cell interactions by quantifying the interaction between the SARS-CoV-2 receptor binding domain (RBD) and its cellular receptor angiotensin-converting enzyme 2 (ACE2) both in living cells and in vitro. We have successfully used this novel biosensor to analyze SARS-CoV-2 RBD mutants and evaluated candidate small molecules (SMs), antibodies, and peptides that may block RBD:ACE2 interaction. This simple, rapid, and HTP biosensor tool will significantly expedite the detection of viral mutants and the anti-COVID-19 drug discovery process.
Subject
COVID-19; SARS-CoV-2; ACE2; RBD; NanoBiT; bioluminescent biosensor; therapeutic drugs
Genre
Article
Type
Text
Language
eng
Date Available
2021-07-15
Provider
Vancouver : University of British Columbia Library
Rights
CC BY 4.0
DOI
10.14288/1.0400197
URI
http://hdl.handle.net/2429/78984
Affiliation
Medicine, Faculty of; Non UBC; Medicine, Department of
Citation
Viruses 13 (6): 1055 (2021)
Publisher DOI
10.3390/v13061055
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
https://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

CC BY 4.0